Keros Therapeutics to Present at Goldman Sachs 45th Global Healthcare Conference

Keros Therapeutics, Inc., a biopharmaceutical company based in Lexington, Massachusetts, announced its participation in the upcoming Goldman Sachs 45th Annual Healthcare Conference. The event is scheduled for June 10, 2024, and Keros' President and CEO, Jasbir S. Seehra, Ph.D., will deliver a fireside chat presentation at 2:40 p.m. Eastern time. The presentation will be accessible via a live audio webcast, the link to which is https://cc.webcasts.com/gold006/061024a_js/?entity=139_TKJ7WHC. Additionally, an archived replay will be available on Keros' website for 90 days post-event.

Keros specializes in the discovery, development, and commercialization of innovative treatments aimed at addressing disorders linked to the dysfunctional signaling of the transforming growth factor-beta (TGF-ß) family of proteins. These proteins are essential in regulating the growth, repair, and maintenance of various tissues such as blood, bone, skeletal muscle, adipose, and heart tissue. By leveraging their in-depth knowledge of TGF-ß, Keros is pioneering the development of protein therapeutics with the goal of offering significant, potentially disease-modifying benefits to patients.

The company's leading product candidate, KER-050 (elritercept), aims to treat cytopenias, including anemia and thrombocytopenia, in patients suffering from myelodysplastic syndrome and myelofibrosis. The second product candidate, KER-012 (cibotercept), targets the treatment of pulmonary arterial hypertension and cardiovascular disorders. Furthermore, KER-065 is being developed to address obesity and neuromuscular diseases.

Keros Therapeutics continues to establish itself as a leader in understanding and harnessing the therapeutic potential of the TGF-ß family of proteins. The company's approach is rooted in a profound comprehension of these proteins' roles as master regulators of critical physiological processes across various tissue types.

For those interested in following the details of the fireside chat presentation and learning more about Keros' advancements in biopharmaceuticals, the live audio webcast and subsequent archived replay provide a valuable opportunity to gain insights into the company's progress and future directions. The archived replay will remain accessible in the Investors section of Keros' website for a duration of 90 days after the event, ensuring that stakeholders and interested parties can catch up on the presentation at their convenience.

Keros Therapeutics' participation in such a prestigious conference underscores its commitment to advancing novel therapeutic options for patients with complex medical conditions. With a focused strategy on leveraging TGF-ß signaling pathways, Keros stands at the forefront of biopharmaceutical innovation, dedicated to bringing groundbreaking treatments to market.